{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:09:27Z","timestamp":1778512167849,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773608"],"award-info":[{"award-number":["81773608"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277087"],"award-info":[{"award-number":["22277087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003818"],"award-info":[{"award-number":["82003818"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1\\u2013030"],"award-info":[{"award-number":["2021-I2M-1\\u2013030"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115831","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T17:18:14Z","timestamp":1695662294000},"page":"115831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors"],"prefix":"10.1016","volume":"261","author":[{"given":"Shengchao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongmei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-8740","authenticated-orcid":false,"given":"Xingyue","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115831_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115831_bib2","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115831_bib3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115831_bib4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Baker","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115831_bib5","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.3390\/ijerph18158008","article-title":"Factors associated with mortality among elderly people in the COVID-19 pandemic (SARS-CoV-2): a systematic review and meta-analysis","volume":"18","author":"Alves","year":"2021","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.ejmech.2023.115831_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21","volume":"399","author":"Wang","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115831_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115831_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/B978-0-12-809633-8.21501-X","article-title":"Human coronavirus-229E, -OC43, -NL63, and -HKU1 (coronaviridae)","author":"Liu","year":"2021","journal-title":"Encycl. Virol."},{"key":"10.1016\/j.ejmech.2023.115831_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","article-title":"Accelerating antiviral drug discovery: lessons from COVID-19","volume":"22","author":"von Delft","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115831_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115831_bib11","doi-asserted-by":"crossref","first-page":"12256","DOI":"10.1021\/acs.jmedchem.0c00502","article-title":"Inhibitors of SARS-CoV-2 entry: current and future opportunities","volume":"63","author":"Xiu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib12","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","volume":"65","author":"Cannalire","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.accounts.2c00735","article-title":"SARS-CoV-2 main protease drug design, assay development, and drug resistance studies","volume":"56","author":"Tan","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.115831_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/acscentsci.2c01359","article-title":"Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro","volume":"9","author":"Hou","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2023.115831_bib15","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib16","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1021\/acs.jmedchem.2c01627","article-title":"Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic Cysteine","volume":"66","author":"Brewitz","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib17","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro)","volume":"65","author":"Han","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41564-022-01119-7","article-title":"An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron","volume":"7","author":"Quan","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115831_bib19","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1021\/acs.jmedchem.1c00566","article-title":"Discovery and mechanism of SARS-CoV-2 main protease inhibitors","volume":"65","author":"Huff","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib20","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115831_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.apsb.2021.08.027","article-title":"Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors","volume":"12","author":"Gao","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115831_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.apsb.2021.06.016","article-title":"Recent advances in developing small-molecule inhibitors against SARS-CoV-2","volume":"12","author":"Xiang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115831_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115311","article-title":"Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: design, synthesis, biological evaluation, and X-ray structure determination","volume":"253","author":"Stefanelli","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112527","article-title":"A promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir","volume":"201","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112711","article-title":"The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115320","article-title":"Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2","volume":"253","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114295","article-title":"Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2","volume":"235","author":"Juang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/med.21940","article-title":"Therapeutic potential of salicylamide derivatives for combating viral infections","volume":"43","author":"Xu","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115831_bib31","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with covid-19","volume":"384","author":"Kalil","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115831_bib33","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115831_bib34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2208822","article-title":"VV116 versus nirmatrelvir\u2013ritonavir for oral treatment of covid-19","volume":"388","author":"Cao","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115831_bib35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115831_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115831_bib37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coph.2021.11.006","article-title":"Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance","volume":"62","author":"Chakraborty","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115831_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115831_bib39","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/med.21664","article-title":"Medicinal chemistry strategies toward host targeting antiviral agents","volume":"40","author":"Ji","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115831_bib40","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1021\/acs.jmedchem.2c01229","article-title":"Antitarget, anti-SARS-CoV-2 leads, drugs, and the drug discovery\u2013genetics alliance perspective","volume":"66","author":"Pozzi","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib41","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","article-title":"Phenotypic drug discovery: recent successes, lessons learned and new directions","volume":"21","author":"Vincent","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115831_bib42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: an industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115831_bib43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1021\/acsinfecdis.0c00478","article-title":"Therapeutic potential of nitazoxanide: an appropriate choice for repurposing versus SARS-CoV-2?","volume":"7","author":"Stachulski","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115831_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115831_bib45","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115831_bib46","doi-asserted-by":"crossref","first-page":"10268","DOI":"10.1021\/acs.jmedchem.6b01301","article-title":"Design and synthesis of cajanine analogues against hepatitis C virus through down-regulating host chondroitin sulfate N-acetylgalactosaminyltransferase 1","volume":"59","author":"Ji","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.apsb.2011.06.005","article-title":"Total synthesis of cajanine and its antiproliferative activity against human hepatoma cells","volume":"1","author":"Ji","year":"2011","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115831_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejmech.2015.06.008","article-title":"Novel cajaninstilbene acid derivatives as antibacterial agents","volume":"100","author":"Geng","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115831_bib49","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3389\/fphar.2018.01201","article-title":"Polypharmacology or promiscuity? Structural interactions of resveratrol with its bandwagon of targets","volume":"9","author":"Saqib","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115831_bib50","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/ijms18091929","article-title":"Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral","volume":"18","author":"Hu","year":"2017","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:20:22Z","timestamp":1778509222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423007985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":50,"alternative-id":["S0223523423007985"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115831","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115831"}}